

SYNTHESIS AND MOLECULAR-BIOLOGICAL ACTIVITY OF THE PYRIDINE ANALOGUE  
OF CARDIOTONIC STEROIDS

Jerzy Wicha<sup>a)\*</sup>, Marek Masnyk<sup>a)</sup>, Werner Schönfeld<sup>b)</sup>, and Kurt R. H. Repke<sup>b)</sup>

a) Institute of Organic Chemistry of the Polish Academy of Sciences,  
Kasprzaka 44, 01-224 Warsaw, Poland, b) Central Institute of Molecular  
Biology of the Academy of Sciences GDR, Berlin-Buch, G.D.R.

**Abstract** -- Pyridylandrostandane derivative 1 was synthesized from compound 4 and shown to exert remarkably high molecular-biological activity in the Na,K-ATPase test for cardiotonic steroids.

Recently one of our groups has reported its preliminary results on the model synthesis of pyridine- and pyridone-androstane derivatives related to cardiotonic steroids.<sup>1)</sup> This communication has prompted Wiesner and his collaborators to present their synthesis of azabufalin<sup>2)</sup>. Now we wish to report the synthesis of 17 $\beta$ -(3'-pyridyl)-14 $\beta$ -androst-4-ene-3 $\beta$ ,14-diol 1 which differs from scillarenin 2 and canarigenin 3 only in the nature of the heterocycle at the position 17 $\beta$  (Scheme 1), and to disclose the biological activity of the target compound 1, its natural counterparts 2 and 3, as well as the synthetic intermediates 9, 10, and 11 in the Na,K-ATPase test for cardiotonic steroids<sup>3)</sup> (Table 1).

The readily accessible<sup>4)</sup> hydroxy-ketone 4a was converted to its tetrahydropyranyl ether 4b (dihydropyran, p-TSA in CH<sub>2</sub>Cl<sub>2</sub>), and the latter compound, dissolved in ether, was treated at -78°C with 3-pyridyllithium prepared<sup>5)</sup> from 3-bromopyridine and n-butyllithium. The addition product thus obtained was acetylated with acetic anhydride in pyridine in the presence of N,N-dimethyl-4-aminopyridine, subsequently the tetrahydropyranyl group was split off with p-TSA in acetone, and the resulting alcohol was acetylated with acetic anhydride in pyridine to afford compound<sup>6)</sup> 5 in 80% overall yield;  $\nu_{\max}$  1735 cm<sup>-1</sup>; <sup>1</sup>H NMR  $\delta$ (ppm) 8.48 (2H, m, C<sub>21</sub>- and C<sub>24</sub>-H), 7.46(1H, d, J=8Hz, C<sub>22</sub>-H), 7.24(1H, dd, J=8Hz, J=5Hz, C<sub>23</sub>-H), 6.43 (1H, dd, J=6Hz, J=2Hz, C<sub>15</sub>-H), 6.28(1H, d, J=6Hz, C<sub>16</sub>-H), 5.36(1H, m, C<sub>6</sub>-H), 4.50(1H, m, C<sub>5</sub>-H), 2.03(3H, s, COOCH<sub>3</sub>), 1.98(3H, s, COOCH<sub>3</sub>), 1.10 and 0.98 (angular CH<sub>3</sub>).



Hydrolysis of ester group in 8 (KOH-MeOH) followed by Oppenauer oxidation (aluminum isopropoxide, cyclohexanone, toluene) furnished the  $\alpha,\beta$ -unsaturated ketone 9; 86% yield; m.p. 170-173°C;  $\nu_{\max}$  1680  $\text{cm}^{-1}$ ;  $^1\text{H NMR}$   $\delta(\text{ppm})$  5.76(1H, s, C<sub>4</sub>-H), 5.35(1H, m, C<sub>15</sub>-H), 1.23 and 0.65 (angular CH<sub>3</sub>).

The compound 9 was reacted with N-bromoacetamide in the presence of perchloric acid in aqueous dioxane<sup>9</sup>) for 1.5 h. The reaction mixture was made alkaline with 10% KOH which resulted in the transformation of intermediate bromohydrin to epoxide 10; m.p. 213-215°C;  $\nu_{\max}$  1675  $\text{cm}^{-1}$ ;  $^1\text{H NMR}$   $\delta(\text{ppm})$  5.70(1H, s, C<sub>4</sub>-H), 3.50(1H, s, C<sub>15</sub>-H), 1.18 and 0.52 (angular CH<sub>3</sub>).

The carbonyl group in compound 10 was selectively and stereospecifically reduced with lithium tri(tert-butoxy)aluminum hydride<sup>10</sup>) to give 3 $\beta$ -hydroxy compound 11 in 95% yield; m.p. 202-204°C;  $^1\text{H NMR}$   $\delta(\text{ppm})$  5.31(1H, s, C<sub>4</sub>-H), 4.15(1H, m, C<sub>3</sub>-H), 3.48(1H, s, C<sub>15</sub>-H), 1.05 and 0.59 (angular CH<sub>3</sub>).

Finally, the epoxide ring in compound 11 was reduced with LiAlH<sub>4</sub> in boiling THF to give the diol 1 in 92% yield;  $\nu_{\max}$  3600  $\text{cm}^{-1}$ ;  $^1\text{H NMR}$   $\delta(\text{ppm})$  8.49(1H, br s, C<sub>21</sub>-H), 8.37(1H, d, J=5Hz, C<sub>24</sub>-H), 7.72(1H, d, J=8Hz, C<sub>22</sub>-H), 7.16(1H, dd, J=8Hz, J=5Hz, C<sub>23</sub>-H), 5.29(1H, s, C<sub>4</sub>-H), 4.14(1H, m, C<sub>3</sub>-H), 2.80(1H, m, C<sub>17</sub>-H), 0.98 and 0.51 (angular CH<sub>3</sub>).

The molecular-biological activities of the compounds examined are compiled in the Table 1. These are expressed in terms of the concentration producing, in the equilibrium state, half-maximum inhibition of the enzyme activity, I<sub>50</sub> values.

Table 1

Molecular-biological activity as characterized by the concentrations required to affect half-maximum inhibition of the activity of Na,K-ATPase from cardiac muscles of guinea-pig and man.

Compound	Guinea-pig enzyme, I <sub>50</sub> $\mu\text{M}$	Human enzyme, I <sub>50</sub> $\mu\text{M}$
<u>1</u>	1.6	0.13
<u>2</u>	0.22	not determined
<u>3</u>	2.5	not determined
<u>9</u>	not determined	46
<u>10</u>	13	6.4
<u>11</u>	15	1.8

As can be seen from Table 1, biological activity is weakened after formal replacement of the pentadienolide- by the pyridine-substituent (2→1) but at least maintained after formal replacement of butenolide- by pyridine-substituent (3→1). The observed gradation of biological activity of pyridine derivatives 1)11)9 is similar to that of corresponding butenolide derivatives, namely 3β-acetoxy-14-hydroxy-5β,14β-card-20(22)-enolide ( $I_{50}=1.2\mu M$ ), 3β-acetoxy-14,15β-epoxy-5β,14β-card-20(22)-enolide ( $I_{50}=11\mu M$ ), and 3β-acetoxy-5β-card-14,20(22)-dienolide ( $I_{50}\gg 100\mu M$ ). Apparently, compounds in the two compared series interact with the same binding site area of Na,K-ATPase, which implies that the pyridine androstane derivative 1 is a true analogue of natural cardiotonics 2 and 3. It is of relevance that 17β-(3'-furyl)-steroid derived from digitoxigenin<sup>11)</sup>, likewise devoid of carbonyl group in the side substituent, exhibit cardiotonic activity comparable to the natural cardenolides.<sup>12)</sup>

#### REFERENCES AND FOOTNOTES

- 1) J.Wicha and M.Masnyk, Heterocycles, 1981, 16, 521
- 2) M.S.Shiao, T.Y.R.Tsai, and K.Wiesner, Heterocycles, 1981, 16, 1979.
- 3) K.R.H.Repke and F.Dittrich, Trends Pharmacol. Sci., 1981, 1, 398.
- 4) R.W.Kelly and P.J.Sykes, J.Chem.Soc. C, 1968, 416.
- 5) H.Gilman and S.M.Spatz, J.Org.Chem., 1951, 16, 1485
- 6) All new compounds had the expected spectral data and satisfactory analyses for C,H,N (crystals) or high-resolution mass spectra (oils).
- 7) This product was accompanied by the corresponding 5,14,16-triene, m.p. 160°C.
- 8) For review see: C.E.Miller, J.Chem.Educ., 1965, 42, 254.
- 9) Ch.R.Engel and G.Bach, Steroids, 1964, 3, 593.
- 10) O.H.Wheeler and J.L.Mateos, Can.J.Chem., 1958, 36, 1431.
- 11) T.Mineshita, R.Hirota, S.Kimoto, M.Uno, and Y.Uemura, Ann. Rep. Shionogi Res. Lab., 1968, 18, 94
- 12) We are indebted to the referee for bringing up to our attention this reference.

Received, 13th July, 1982